Find and Pitch Jounalists, Get Your Story Covered

Tags: Celltrion subcutaneous infliximab inflammatory bowel disease infliximab infection

	Profile	Recent Articles on Subject
1	Greg Laub MedPage Today Director of Video at MedPage Today. Screenwriter, previous managing editor. videographyscreenwritingediting	Inebilizumab for Myasthenia Gravis Reduces Steroid Burden - 11 days ago Dupilumab Reduces Airway Inflammation, Mucus Plugs in Asthma Patients - 8 months ago Daratumumab Added to Standard Therapy Improves PFS in Multiple Myeloma - 11 months ago Responses to Mosunetuzumab in Follicular Lymphoma Remain Durable at 3 Years - 11 months ago Positive Results for Odronextamab in Relapsed/Refractory DLBCL - 11 months ago New Data on Bimekizumab in Psoriatic Arthritis - 12 months ago Ubamatamab Shows Some Activity in Recurrent Ovarian Cancer - 12 months ago A Novel Mechanism of Action in Treating Relapsing MS - about 1 year ago New Data on CD40 Ligand Inhibitor for Relapsing MS - about 1 year ago
2	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	FDA Accepts Biologic License Application for Biosimilar Denosumab - 18 days ago Non-Medical Switch to Infliximab Biosimilar Demonstrates Similar Outcomes for IBD - 2 months ago FDA Approves Guselkumab for Treatment of Ulcerative Colitis - 2 months ago FDA Approves Epcoritamab for Treatment of Relapsed, Refractory Follicular Lymphoma - 5 months ago FDA Accepts sBLA for Bimekizumab-bkzx in Hidradenitis Suppurativa Treatment - 8 months ago FDA Approves Tocilizumab-aazg as Biosimilar to Actemra for Multiple Indications - 9 months ago Results Show Dupilumab Reduces Airway Inflammation In Asthma - 9 months ago FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma - 9 months ago FDA Approves Adalimumab-ryvk as Interchangeable Biosimilar for Humira - 9 months ago Biosimilar Adalimumab, Etanercept Have Equivalent Effectiveness to Reference Drugs Over 48 Months - 9 months ago Celltrion Seeks Approval From FDA for CT-P47 as Biosimilar of Tocilizumab - 10 months ago FDA Approves Targeted Release Budesonide for Treatment of Primary Immunoglobulin A Nephropathy - 11 months ago Belantamab Mafodotin Met Primary Endpoint for Those with Relapsed, Refractory Multiple Myeloma - 12 months ago FDA Grants Breakthrough Therapy Designation to Epcoritamab for Follicular Lymphoma - 12 months ago FDA Accepts Supplemental Biologics License Application for Hadlima for Interchangeability With Humira - about 1 year ago Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers - about 1 year ago Subcutaneous Lecanemab Demonstrates Greater Amyloid Plaque Removal Than Intravenous Lecanemab - about 1 year ago
3	Kristen Monaco MedPage Today	Complement Inhibitor Shows Promise for Rare Kidney Disorder - 20 days ago Alternative Pathway Inhibition Makes Good in IgA Nephropathy - 22 days ago
4	John Pinching PharmaTimes Next-gen biopharma company. La Jolla, California biopharmadrugsdevices	Celltrion unveils promising dose escalation results for subcutaneous infliximab - about 1 month ago Amgen’s trial brings new hope for IgG4-RD patients - 5 months ago
5	Mike Bassett MedPage Today Explains healthcare complexities. Not endorsements. New York, New York Healthcare journalism	Retifanlimab-Chemo Combo Boosts PFS in Advanced Squamous Cell Anal Cancer - 2 months ago Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC - 2 months ago Targeted First-Line Combo Approved for EGFR-Mutated Lung Cancer - 3 months ago New First-Line Option for Pancreatic Cancer Approved - 9 months ago Axatilimab Shows Efficacy in Recurrent/Refractory GVHD - 11 months ago Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer - about 1 year ago Antibody-Drug Conjugate Improves PFS in Pretreated Breast, Lung Cancers - about 1 year ago
6	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	Lebrikizumab Wins FDA Approval for Eczema - 2 months ago FDA OKs Amivantamab as First-Line Lung Cancer Treatment - 9 months ago JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma - 11 months ago Frontline Venetoclax-Ibrutinib for CLL Boosts Survival in Fit Patients - 11 months ago
7	Jonathan Wosen STAT News West Coast Biotech Reporter. Formerly @sdut. Stanford PhD. UCSC alum. San Diego, California BiotechLife SciencesImmunology	STAT+: FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug - 2 months ago STAT+: FDA approves Lilly ulcerative colitis treatment with a new approach to tamping down inflammation - about 1 year ago
8	John Gever MedPage Today MedPage Today factotum. Pittsburgh, Pa. Healthcare journalism	Off-the-Shelf Drug Matches CAR-T Effects in Refractory Lupus - 2 months ago Medicare Lags, Medicaid Leads for Biosimilar Uptake - 4 months ago Study Confirms: No Great Options for Treating VEXAS - 6 months ago Novel IL-17A Blocker Continues to Impress in PsA - about 1 year ago Novel Drug OK'd for Ulcerative Colitis - about 1 year ago Bimekizumab Data in axSpA Look Good Through 1 Year - about 1 year ago
9	Alana Hippensteele, Managing Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	FDA Approves Axatilimab-csfr for cGVHD - 3 months ago
10	Kennedy Ferruggia, Assistant Editor Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	New Study Assesses Ifinatamab Deruxtecan for Treatment of Small Cell Lung Cancer - 3 months ago J&J Submits sBLA To FDA for Guselkumab in Ulcerative Colitis - 8 months ago Treatment With Anifrolumab-fnia Shows Promising Rates of Remission for Lupus - about 1 year ago

Journalists covering infliximab